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Obesity remains a prominent public health
concern in the United States as well as
many other countries, with 33% of adults
worldwide overweight or obese in 2005
and an estimated 60% by 2030 (Kelly
et al., 2008). This data highlights the need
for effective prevention and intervention
strategies. Obesity can be viewed as an
endpoint with many possible contribut-
ing factors, including genetic propensity,
sedentary lifestyles, and the relative ease
with which one can obtain food, partic-
ularly in modern industrialized societies.
Such factors may result in an imbalance
between the number of calories consumed
vs. expended. The majority of pharma-
ceutical compounds that have been devel-
oped to combat obesity aim to correct
or improve this last factor by suppressing
appetite (See Table 1). However, the num-
ber of people with obesity in the United
States does not appear to be decreas-
ing (Flegal et al., 2012). Here we present
some possible reasons why these drugs
have failed to fully address the problem of
obesity.
First, the weight loss associated with the
appetite suppressant drugs on the market
is not as dramatic as one might expect.
For example, one drug which received
FDA approval in 2012, Belviq, has been
found to result in a mean weight loss
of 3–3.6%, corrected for the effects of
placebo, in phase III clinical trials (Miller,
2013). Another recently approved drug,
Qsymia, which consists of a combination
of phentermine and extended-release top-
iramate, an anti-epileptic drug, has shown
greater effects, producing a mean weight
loss of between 7.5 and 9.3%, corrected
for the effects of placebo, during phase III
clinical trials (Garvey, 2013). While these
medications may be more or less effective
for certain individuals, especially in light
of other lifestyle changes, and these reduc-
tions are certainly beneficial, they do not
appear to be the definitive weight loss
interventions.
Second, suppressing appetite may be
too simplistic of an approach. Instead of
aiming to reduce intake of all types of
foods, it may be more beneficial over the
long term to specifically reduce excessive
intake of foods rich in fats or sugars, which
can contain excessive amounts of calories
but offer minimal nutritional value. To
our knowledge, no appetite suppressant
on the market to date has been known to
reduce intake of specific types of food. This
approach may facilitate the normalization
of eating patterns by decreasing overcon-
sumption of less healthy options without
affecting intake of sources of greater nutri-
tion. Further, recent research suggests that
the age old adage “a calorie is a calo-
rie” is not exactly true. Not all calories
are created equal. For example, research
has found that there are differences in
the effects of equicaloric diets comprised
of different proportions of macronutri-
ents (Ebbeling et al., 2012). Resting and
total energy expenditure has been shown,
for instance, to be most decreased in
response to a low-fat diet, compared to
low glycemic index and low carbohy-
drate diets, without differences in physi-
cal activity, suggesting that diets consisting
of varying macronutrient compositions
can differentially affect one’s metabolism.
Further, this finding supports the hypoth-
esis that targeted pharmacotherapy may be
beneficial.
It is also possible that appetite sup-
pressants may not have worked well
for obesity because these medica-
tions have targeted appetite in general,
rather than targeting the mechanisms of
reinforcement associated with food intake,
as has been initiated in the past with the
endocannabinoid system (Carai et al.,
2006). Targeting neural reward systems
may also, in turn, result in a selective sup-
pression of appetite for certain types of
highly reinforcing foods. Findings from
our laboratory and others have revealed
that overconsumption, or binge consump-
tion, of sugars and fats can lead to brain
and behavioral changes similar to those
seen within the context of drug addic-
tion, providing empirical support for the
concept of food addiction (Avena et al.,
2008; Oswald et al., 2011; Iemolo et al.,
2012; Rossetti et al., 2013). Such findings
point to one potential reason that weight
loss may be so challenging for some, but
also provide an avenue to study poten-
tial treatments that consider and address
the effects that these ingredients can have
on the brain. In light of the similarities
between binge intake of highly palatable
foods and drug addiction, our laboratory
and others have been interested in study-
ing the effects of medications that have
been used to treat substance use disorders
on overeating. For example, the GABA-B
agonist, baclofen, which has been found
to be effective in treating several aspects of
alcohol dependence in many (Addolorato
et al., 2000, 2007, 2011) but not all studies
(Garbutt et al., 2010), has also been shown
to aid in the reduction of binge eating
behavior in both preclinical and clinical
studies (Buda-Levin et al., 2005; Broft
et al., 2007; Berner et al., 2009; Corwin
et al., 2012). Additionally, baclofen has
shown some success in inhibiting weight
gain in animals and promoting weight loss
in clinical samples (Sato et al., 2007; Arima
and Oiso, 2010; Patel and Ebenezer, 2010).
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Table 1 | Current pharmaceutical treatments of obesity.
Name Approved Type of compound Proposed mechanism of action
Phentermine 1959 Sympathomimetic amine Appetite suppressant
Fenfluramine*, Dexfenfluramine* Serotonergic agent Appetite suppressant
Benzphetamine Sympathomimetic amine Appetite suppressant
Phendimetrazine 1979 Sympathomimetic amine Appetite suppressant
Diethylpropion Sympathomimetic amine Appetite suppressant
Sibutramine* 1997 Noradrenaline and serotonin reuptake
inhibitor
Appetite suppressant (also
stimulates thermogenesis)
Orlistat 1999 Lipase inhibitor Inhibits the absorption of dietary fat
Phentermine/Topiramate 2012 Sympathomimetic
amine/sulfamate-substituted monosaccharide
Appetite suppressant
Lorcaserin 2012 Selective serotonin 2C receptor agonist Appetite suppressant
*Removed from the market.
Using the food addiction model in the
laboratory may be an innovative approach
to identifying potential weight loss treat-
ments which take into account the neu-
rochemical effects of regularly overeating
certain macronutrients. In clinical sam-
ples, 25% of participants who are obese
meet the diagnostic criteria for “food
addiction,” according to the Yale Food
Addiction Scale (YFAS) (Davis et al.,
2011). Studies assessing obese individu-
als with binge eating disorder have found
that 42–57% participants meet this cri-
teria (Gearhardt et al., 2012, 2013), and
the percentage of obese individuals seek-
ing bariatric surgery who meet this criteria
is 42% (Meule et al., 2012). Thus, while
not all individuals who are obese express
addiction-like characteristics or behaviors
regarding food, there are a significant
number of individuals who do, and who
may thus benefit from addiction-targeting
treatments. One avenue for this research
includes the study of medications that
have been successful in treating substance
use disorders (Gold and Avena, 2013).
With redefined goals in mind, includ-
ing a greater focus on the reduction of
overeating specific foods, such research
may lead to the development of more tar-
geted weight loss treatments.
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